Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019. Study of Efficacy and Safety Based on Finisterian Data Compared to Data in the Literature.

NCT04573933 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT04573933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04573933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019. Study of Efficacy and Safety Based on Finisterian Data Compared to Data in the Literature.
Lead sponsor
University Hospital, Brest
Phase
Observational
Overall status
Completed
Start date
June 29, 2020
Completion date
August 29, 2020
Enrollment
54 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasm